THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Otezla (apremilast) is a brand-name oral tablet that’s prescribed for conditions such as psoriatic arthritis. The drug’s cost with and without insurance can depend on several factors, such as whether ...

Biopharmaceutical giant Amgen announced Monday it has agreed to buy popular psoriasis and psoriatic-arthritis drug Otezla from Celgene for $13.4 billion. The deal helps clear the way for Amgen’s ...

Headache, upper respiratory infection, and nausea are some of Otezla’s more common side effects. As your body gets used to Otezla, some side effects may reduce or go away. This can take around 2 weeks ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

--Amgen today announced Otezla ® improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area affected by the disease, according to ...

Amgen has won a crunch appeals court ruling that delays generic competition to its big-selling psoriasis drug Otezla in the US until 2028, although it missed out on getting a longer period of ...

NICE has issued a final appraisal determination recommending Celgene's Otezla for adults with active psoriatic arthritis, reversing an earlier decision to reject the drug. The oral drug is Celgene's ...

With the Federal Trade Commission (FTC) sweating the details of Bristol-Myers Squibb and Celgene’s proposed $74 billion merger, all eyes were on the companies’ combined psoriasis portfolio, which ...